Abstract:
The rapid growth of nanonutritionals and probiotics has provided both opportunities and challenges in global health and regulatory science. While these medicines offer increased bioavailability, targeted distribution, and superior treatment outcomes, their incorporation into consumer markets is hampered by fragmented and uneven regulatory frameworks. This review critically examines international approaches to safety evaluation, labeling, and standardization, with a focus on significant markets such as the United States, the European Union, India, and the Asia-Pacific region. Comparative evaluations of regulatory adequacy scores show significant differences in nano disclosure, probiotic strain identification, CFU criteria, and health claim clearance. Safety issues such as nanoparticle toxicity, bioaccumulation, and probiotic strain diversity highlight the importance of testing techniques that go beyond traditional toxicology. Current labelling practices are inconsistent, limiting customer awareness and confidence. Harmonization initiatives by the WHO, Codex Alimentarius, ISO, and regional agencies show progress, but are insufficient to address transnational trade and public health threats. Future trends, such as AI-driven predictive toxicology, modified probiotics, and sustainable nanotechnology, provide both potential and regulatory challenges. The study shows that stronger international collaboration, consistent safety measures, and transparent labelling are required to combine innovation with consumer protection and progress toward a unified worldwide regulatory framework for nano-nutraceuticals and probiotics. 

Keywords: 

Nano nutraceuticals, Probiotics, Regulatory gaps, Safety assessment, Global standards, Pharmaceutical regulation, Nanotechnology, Microbiome, Harmonization, Innovation.

Introduction:

Over the last three decades, the way nutraceuticals and probiotics are regulated has changed a lot. At first, regulators didn’t pay much attention to these products, treating them mostly as normal food because the science wasn’t well-understood and the market was small. But as probiotics became more common in the late 1900s, there was a push to set safety and performance standards for specific strains, even if companies exaggerated what their products could do in their ads. [4].  Around the year 2000, things shifted when nanotechnology came into play, which sparked new questions for regulators. Because nanomaterials are more reactive, can be absorbed more easily, and might be toxic, groups like the European Food Safety Authority (EFSA) and the U.S. Food and Drug Administration (FDA) came up with new ways to test them. These methods needed a full description of their physical and chemical traits, toxicology tests, and risk evaluations that were very different from how regular materials were checked. At the same time, rules for probiotics were getting better because of teamwork across different countries.[4]. In May of 2019, ISAPP gathered a group of experts to broaden the definition of synbiotics, agreeing that a synbiotic is a mix of living microorganisms and substances used by host microorganisms that benefits the host’s health. This included two types: complementary and synergistic synbiotics, which helped create better product designs and clearer pathways for getting approval. Even so, rules for probiotics around the world are still not aligned, and what kind of proof is needed for health claims differs a lot from one country to another. [5]. This came in two forms — complementary and synergistic synbiotics – which could improve product designs and provide a clearer path to approval.. Nevertheless, global regulations on probiotics remain divergent, with the type of evidence needed for health claims varying greatly between nations [5]. Regulators have usually reacted to problems instead of anticipating them, often trailing behind product growth and sales. This delay has caused inconsistent oversight, uneven protection for customers, and ongoing market doubt for both probiotics and nano nutraceuticals

References

[1]     Rathod *, Devidas V, Hingane MLD, Pharm M, Rokade MVG. Role of Nanotechnology in Nutraceuticals. International Journal of Pharmaceutical Research and Applications n.d.;6:753–64. https://doi.org/10.35629/7781-0601753764.

[2] Arratia-Quijada J, Nuño K, Ruíz-Santoyo V, Andrade-Espinoza BA. Nano-encapsulation of probiotics: Need and critical considerations to design new non-dairy probiotic products. J Funct Foods 2024;116. https://doi.org/10.1016/j.jff.2024.106192.

[3] Amjad S, Serajuddin M. Nanoparticle Drug Delivery: An Advanced Approach for Highly Competent and Multifunctional Therapeutic Treatment. Modeling and  Control of Drug Delivery Systems, Elsevier; 2021, p. 183–93. https://doi.org/10.1016/B978-0-12-821185-4.00008-7.

[4] The Nanomedicine Revolution, Part 3. n.d.

[5] Swanson KS, Gibson GR, Hutkins R, Reimer RA, Reid G, Verbeke K, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol 2020;17:687–701. https://doi.org/10.1038/s41575-020-0344-2.

[6] Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use. Emerg Infect Dis 2010;16:1661–5. https://doi.org/10.3201/eid1611.100574.

[7] Arora M, Baldi A. Regulatory categories of probiotics across the globe: A review representing existing and recommended categorization. Indian J Med Microbiol 2015;33:S2–10. https://doi.org/10.4103/0255-0857.150868.

[8] Huggett AC, Conzelmann C. EU regulation on novel foods: Consequences for the food industry. Trends Food Sci Technol 1997;8:133–9. https://doi.org/10.1016/S0924-2244(97)01022-4.

[9] Blaze J. A Comparison of Current Regulatory Frameworks for Nutraceuticals in Australia, Canada, Japan, and the United States. Innov Pharm 2021;12:8. https://doi.org/10.24926/iip.v12i2.3694.

[10] Tripathy S, Verma DK, Gupta AK, Srivastav PP, Patel AR, Chávez González ML, et al. Nanoencapsulation of biofunctional components as a burgeoning nanotechnology-based approach for functional food development: A review. Biocatal Agric Biotechnol 2023;53:102890. https://doi.org/10.1016/j.bcab.2023.102890.

[11] Martirosyan A, Schneider YJ. Engineered nanomaterials in food: Implications for food safety and consumer health. Int J Environ Res Public Health 2014;11:5720–50. https://doi.org/10.3390/ijerph110605720.

[12] Chaudhry Q, Scotter M, Blackburn J, Ross B, Boxall A, Castle L, et al. Applications and implications of nanotechnologies for the food sector. Food Additives and Contaminants - Part A 2008;25:241–58. https://doi.org/10.1080/02652030701744538.

[13] Durazzo A, Nazhand A, Lucarini M, Atanasov AG, Souto EB, Novellino E, et al. An updated overview on nanonutraceuticals: Focus on nanoprebiotics and nanoprobiotics. Int J Mol Sci 2020;21. https://doi.org/10.3390/ijms21072285.

[14] Suganya K, Koo BS. Gut–brain axis: Role of gut microbiota on neurological disorders and how probiotics/prebiotics beneficially modulate microbial and immune pathways to improve brain functions. Int J Mol Sci 2020;21:1–29. https://doi.org/10.3390/ijms21207551.

[15] Sanders ME, Akkermans LMA, Haller D, Hammerman C, Heimbach JT, Hörmannsperger G, et al. Safety assessment of probiotics for human use. Gut Microbes 2010;1:164–85. https://doi.org/10.4161/gmic.1.3.12127.

[16] Zavišić G, Popović M, Stojkov S, Medić D, Gusman V, Jovanović Lješković N, et al. Antibiotic Resistance and Probiotics: Knowledge Gaps, Market Overview and Preliminary Screening. Antibiotics 2023;12:1281. https://doi.org/10.3390/antibiotics12081281.

[17] Cheftel JC. Food and nutrition labelling in the European Union. Food Chem 2005;93:531–50. https://doi.org/10.1016/j.foodchem.2004.11.041.

[18] Fletcher N, Bartholomaeus A. Regulation of Nanotechnologies in Food in Australia and New Zealand. International Food Risk Analysis Journal 2011:1. https://doi.org/10.5772/10685.

[19] Boverhof DR, Bramante CM, Butala JH, Clancy SF, Lafranconi WM, West J, et al. Comparative assessment of nanomaterial definitions and safety evaluation considerations. Regulatory Toxicology and Pharmacology 2015;73:137–50. https://doi.org/10.1016/j.yrtph.2015.06.001.

[20] Gao X, Lowry G V. Progress towards standardized and validated characterizations for measuring physicochemical properties of manufactured nanomaterials relevant to nano health and safety risks. NanoImpact 2018;9:14–30. https://doi.org/10.1016/j.impact.2017.09.002.

[21] Adhikari B, Venkatesh DN. THE NUTRACEUTICAL MARKET: INTELLECTUAL PROPERTY, CLINICAL RESEARCH, AND FUTURE INSIGHTS. International Journal of Applied Pharmaceutics 2025;17:39–52. https://doi.org/10.22159/ijap.2025v17i2.53278.

[22] Lamph S. Regulation of medical devices outside the European Union. J R Soc Med 2012;105 Suppl 1. https://doi.org/10.1258/jrsm.2012.120037.

[23] Beghin JC, Maertens M, Swinnen J. Nontariff measures and standards in trade and global value chains. Annu Rev Resour Economics 2015;7:425–50. https://doi.org/10.1146/annurev-resource-100814-124917.

[24] BORRAZ O. Governing Standards: The Rise of Standardization Processes in France and in the EU. Governance 2007;20:57–84. https://doi.org/10.1111/j.1468-0491.2007.00344.x.

[25] Wilson JS, Mann CL, Otsuki T. Trade Facilitation and Economic Development: Measuring the Impact. World Bank, Washington, DC; 2003. https://doi.org/10.1596/1813-9450-2988.

[26] Yamamoto S. Association of Southeast Asian Nations. The Wiley‐Blackwell Encyclopedia of Globalization, Wiley; 2012. https://doi.org/10.1002/9780470670590.wbeog033.

[27] Widhiyanti HN. The Urgency of Harmonizing Competition Laws in Moving Towards the ASEAN Free Trade Area. Fiat Justisia: Jurnal Ilmu Hukum 2020;14:45–68. https://doi.org/10.25041/fiatjustisia.v14no1.1749.

[28] Participation of Developing Countries in Global Value Chains. vol. 179. 2015. https://doi.org/10.1787/5js33lfw0xxn-en.

[29] Beghin J, Disdier AC, Marette S, Van Tongeren F. Welfare costs and benefits of non-tariff measures in trade: A conceptual framework and application. World Trade Review, vol. 11, 2012, p. 356–75. https://doi.org/10.1017/S1474745612000201.

[30] Visciglia A, Allesina S, Amoruso A, De Prisco A, Dhir R, Bron PA, et al. Assessment of shelf-life and metabolic viability of a multi-strain synbiotic using standard and innovative enumeration technologies. Front Microbiol 2022;13. https://doi.org/10.3389/fmicb.2022.989563.

[31] Feliciano RJ, Guzmán-Luna P, Boué G, Mauricio-Iglesias M, Hospido A, Membré JM. Strategies to mitigate food safety risk while minimizing environmental impacts in the era of climate change. Trends Food Sci Technol 2022;126:180–91. https://doi.org/10.1016/j.tifs.2022.02.027.

[32] Wilson JS, Mann CL, Otsuki T. Trade Facilitation and Economic Development: A New Approach to Quantifying the Impact. World Bank Econ Rev 2003;17:367–89. https://doi.org/10.1093/wber/lhg027.

[33] Lee SY, Yeo SK, Chua CLL. Evaluation of commercial probiotic supplements in Malaysia for registration status, labelling compliance, and probiotic contents. Malays J Nutr 2025;31:013–21. https://doi.org/10.31246/mjn-2024-0030.

[34] Sanders ME, Heimbach JT, Pot B, Tancredi D, Lenoir-Wijnkoop I, Lähteenmäki-Uutela A, et al. Health claims substantiation for probiotic and prebiotic products. Gut Microbes 2011;2:127–33. https://doi.org/10.4161/gmic.2.3.16174.

[35] Dwyer JT, Coates PM, Smith MJ. Dietary supplements: Regulatory challenges and research resources. Nutrients 2018;10. https://doi.org/10.3390/nu10010041.

[36] Siong TE, Hardinsyah, Sum CAS. Status of probiotic regulations in Southeast Asia countries. Malays J Nutr 2021;27:507–30. https://doi.org/10.31246/mjn-2021-27-3-probiotic-regulations-review.

[37] Thakkar S, Anklam E, Xu A, Ulberth F, Li J, Li B, et al. Regulatory landscape of dietary supplements and herbal medicines from a global perspective. Regulatory Toxicology and Pharmacology 2020;114. https://doi.org/10.1016/j.yrtph.2020.104647.

[38] Emerging Nano-Formulation Strategies for Nutraceutical Delivery. Advances in Food Processing and Technology 2023;3. https://doi.org/10.29011/2639-3387.100027.

[39] Dinda AK. Regulatory science: The need for empowering Indian innovation. Indian Journal of Medical Research 2021;154:770–5. https://doi.org/10.4103/ijmr.IJMR_1665_19.

[40] Chávez-Hernández JA, Velarde-Salcedo AJ, Navarro-Tovar G, Gonzalez C. Safe nanomaterials: from their use, application, and disposal to regulations. Nanoscale Adv 2024;6:1583–610. https://doi.org/10.1039/d3na01097j.

[41] Djebbar B, Hellali DH, Merzougui H. A Systematic Review of Nano-Encapsulation for Improving the Bioavailability of Dietary Supplements and Nutraceuticals. Journal of Drug Delivery and Therapeutics 2024;14:129–36. https://doi.org/10.22270/jddt.v14i10.6829.

[42] Oba S, Yildirim T, Karataş ŞM. Probiotics Safety Aspect of Functional Foods. Journal of Culinary Science & Technology 2024;22:1327–56. https://doi.org/10.1080/15428052.2022.2135156.

[43] Food Packaging. MDPI; 2019. https://doi.org/10.3390/books978-3-03897-767-4.

[44] Bai DP, Lin XY, Huang YF, Zhang XF. Theranostics aspects of various nanoparticles in veterinary medicine. Int J Mol Sci 2018;19. https://doi.org/10.3390/ijms19113299.

[45] Genuis SJ, Schwalfenberg G, Siy AKJ, Rodushkin I. Toxic Element Contamination of Natural Health Products and Pharmaceutical Preparations. PLoS One 2012;7. https://doi.org/10.1371/journal.pone.0049676.

[46] Poma A, Di Giorgio ML. Toxicogenomics to Improve Comprehension of the Mechanisms Underlying Responses of In vitro and In vivo Systems to Nanomaterials: A Review. vol. 9. 2008.

[47] Helal NA, Eassa HA, Amer AM, Eltokhy MA, Edafiogho I, Nounou MI. Nutraceuticals’ Novel Formulations: The Good, the Bad, the Unknown and Patents Involved. Recent Pat Drug Deliv Formul 2019;13:105–56. https://doi.org/10.2174/1872211313666190503112040.

[48] Yang W, Wang L, Mettenbrink EM, Deangelis PL, Wilhelm S. Nanoparticle Toxicology. Annual Review of Pharmacology and Toxicology Downloaded from WwwAnnualreviewsOrg Guest (Guest 2021. https://doi.org/10.1146/annurev-pharmtox-032320.

[49] Yuan X, Zhang X, Sun L, Wei Y, Wei X. Cellular Toxicity and Immunological Effects of Carbon-based Nanomaterials. Part Fibre Toxicol 2019;16. https://doi.org/10.1186/s12989-019-0299-z.

[50] Egbuna C, Parmar VK, Jeevanandam J, Ezzat SM, Patrick-Iwuanyanwu KC, Adetunji CO, et al. Toxicity of Nanoparticles in Biomedical Application: Nanotoxicology. J Toxicol 2021;2021. https://doi.org/10.1155/2021/9954443.

[51] Sohal IS, O’Fallon KS, Gaines P, Demokritou P, Bello D. Ingested engineered nanomaterials: State of science in nanotoxicity testing and future research needs. Part Fibre Toxicol 2018;15. https://doi.org/10.1186/s12989-018-0265-1.

[52] Qamar W, Gulia S, Athar M, Ahmad R, Imam MT, Chandra P, et al. An insight into impact of nanomaterials toxicity on human health. PeerJ 2024;12. https://doi.org/10.7717/peerj.17807.

[53] Alsaleh NB. Adverse responses of engineered nanomaterials at low and subtoxic exposure levels: current understanding and future perspectives. Nanotoxicology 2025;19:453–73. https://doi.org/10.1080/17435390.2025.2516493.

[54] Jakic K, Selc M, Razga F, Nemethova V, Mazancova P, Havel F, et al. Long-Term Accumulation, Biological Effects and Toxicity of BSA-Coated Gold Nanoparticles in the Mouse Liver, Spleen, and Kidneys. Int J Nanomedicine 2024;19:4103–20. https://doi.org/10.2147/IJN.S443168.

[55] Jiang J, Oberdörster G, Elder A, Gelein R, Mercer P, Biswas P. Does nanoparticle activity depend upon size and crystal phase? Nanotoxicology 2008;2:33–42. https://doi.org/10.1080/17435390701882478.

[56] Oberdörster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K, et al. Principles for characterizing the potential human health effects from exposure to nanomaterials: Elements of a screening strategy. Part Fibre Toxicol 2005;2. https://doi.org/10.1186/1743-8977-2-8.

[57] Doak SH, Griffiths SM, Manshian B, Singh N, Williams PM, Brown AP, et al. Confounding experimental considerations in nanogenotoxicology. Mutagenesis 2009;24:285–93. https://doi.org/10.1093/mutage/gep010.

[58] Balbus JM, Maynard AD, Colvin VL, Castranova V, Daston GP, Denison RA, et al. Meeting report: Hazard assessment for nanoparticles-report from an interdisciplinary workshop. Environ Health Perspect 2007;115:1654–9. https://doi.org/10.1289/ehp.10327.

[59] Nyazema NZ, Chanyandura JT, Kumar PO. Nanomedicine and regulatory science: the challenges in Africa. Frontiers in Biomaterials Science 2023;2. https://doi.org/10.3389/fbiom.2023.1184662.

[60] Igberaese Clinton Festus-Ikhuoria, Nwankwo Constance Obiuto, Riliwan Adekola Adebayo, Oladiran Kayode Olajiga. Nanotechnology in consumer products: A review of applications and safety considerations. World Journal of Advanced Research and Reviews 2023;21:2050–9. https://doi.org/10.30574/wjarr.2024.21.3.0923.

[61] Musial J, Krakowiak R, Mlynarczyk DT, Goslinski T, Stanisz BJ. Titanium dioxide nanoparticles in food and personal care products—what do we know about their safety? Nanomaterials 2020;10:1–23. https://doi.org/10.3390/nano10061110.

[62] De Jong WH, Borm PJ. Drug delivery and nanoparticles: Applications and hazards. vol. 3. 2008.

[63] Moammeri A, Chegeni MM, Sahrayi H, Ghafelehbashi R, Memarzadeh F, Mansouri A, et al. Current advances in niosomes applications for drug delivery and cancer treatment. Mater Today Bio 2023;23. https://doi.org/10.1016/j.mtbio.2023.100837.

[64] Soares S, Sousa J, Pais A, Vitorino C. Nanomedicine: Principles, properties, and regulatory issues. Front Chem 2018;6. https://doi.org/10.3389/fchem.2018.00360.

[65] Amenta V, Aschberger K, Arena M, Bouwmeester H, Botelho Moniz F, Brandhoff P, et al. Regulatory aspects of nanotechnology in the agri/feed/food sector in EU and non-EU countries. Regulatory Toxicology and Pharmacology 2015;73:463–76. https://doi.org/10.1016/j.yrtph.2015.06.016.

[66] Nile SH, Baskar V, Selvaraj D, Nile A, Xiao J, Kai G. Nanotechnologies in Food Science: Applications, Recent Trends, and Future Perspectives. Nanomicro Lett 2020;12. https://doi.org/10.1007/s40820-020-0383-9.

[67] Holden PA, Gardea-Torresdey JL, Klaessig F, Turco RF, Mortimer M, Hund-Rinke K, et al. Considerations of Environmentally Relevant Test Conditions for Improved Evaluation of Ecological Hazards of Engineered Nanomaterials. Environ Sci Technol 2016;50:6124–45. https://doi.org/10.1021/acs.est.6b00608.

[68] Maurer-Jones MA, Gunsolus IL, Murphy CJ, Haynes CL. Toxicity of engineered nanoparticles in the environment. Anal Chem 2013;85:3036–49. https://doi.org/10.1021/ac303636s.

[69] Deng S, Li C, Cao J, Cui Z, Du J, Fu Z, et al. Organ-on-a-chip meets artificial intelligence in drug evaluation. Theranostics 2023;13:4526–58. https://doi.org/10.7150/thno.87266.

[70] Nair DG, Weiskirchen R. Advanced In vitro Models for Preclinical Drug Safety: Recent Progress and Prospects. Curr Issues Mol Biol 2025;47. https://doi.org/10.3390/cimb47010007.

[71] Brooks SM, Alper HS. Applications, challenges, and needs for employing synthetic biology beyond the lab. Nat Commun 2021;12. https://doi.org/10.1038/s41467-021-21740-0.

[72] Duman-Scheel M. Saccharomyces cerevisiae (Baker’s Yeast) as an Interfering RNA Expression and Delivery System. Curr Drug Targets 2018;20:942–52. https://doi.org/10.2174/1389450120666181126123538.

[73] More S, Bampidis V, Benford D, Bragard C, Halldorsson T, Hernández-Jerez A, et al. Evaluation of existing guidelines for their adequacy for the microbial characterisation and environmental risk assessment of microorganisms obtained through synthetic biology. EFSA Journal 2020;18. https://doi.org/10.2903/j.efsa.2020.6263.

[74] Kussmann M, Abe Cunha DH, Berciano S. Bioactive compounds for human and planetary health. Front Nutr 2023;10. https://doi.org/10.3389/fnut.2023.1193848.

[75] Cassotta M, Cianciosi D, Elexpuru-Zabaleta M, Pascual IE, Cano SS, Giampieri F, et al. Human-based new approach methodologies to accelerate advances in nutrition research. Food Front 2024;5:1031–62. https://doi.org/10.1002/fft2.369.

[76] Siddiqui SA, Khan S, Mehdizadeh M, Nirmal NP, Khanashyam AC, Fernando I, et al. Consumer Studies Focus on Prebiotics, Probiotics, and Synbiotics in Food Packaging: a Review. Current Food Science and Technology Reports 2023;1:13–29. https://doi.org/10.1007/s43555-023-00003-7.

[77] Ashfaq R, Rasul A, Asghar S, Kovács A, Berkó S, Budai-Szűcs M. Lipid Nanoparticles: An Effective Tool to Improve the Bioavailability of Nutraceuticals. Int J Mol Sci 2023;24. https://doi.org/10.3390/ijms242115764.

[78] Maurya V, Shakya A, Aggarwal M, Gothandam KM, Bohn T, Pareek S. Fate of β-Carotene within Loaded Delivery Systems in Food: State of Knowledge 2021. https://doi.org/10.20944/preprints202102.0205.v1.

[79] Ranjha MMAN, Shafique B, Rehman A, Mehmood A, Ali A, Zahra SM, et al. Biocompatible Nanomaterials in Food Science, Technology, and Nutrient Drug Delivery: Recent Developments and Applications. Front Nutr 2022;8. https://doi.org/10.3389/fnut.2021.778155.

[80] Madureira AR, Nunes S, Campos DA, Fernandes JC, Marques C, Zuzarte M, et al. Safety profile of solid lipid nanoparticles loaded with rosmarinic acid for oral use: In vitro and animal approaches. Int J Nanomedicine 2016;11:3621–40. https://doi.org/10.2147/IJN.S104623.

[81] Petrovic SM, Barbinta-Patrascu ME. Organic and Biogenic Nanocarriers as Bio-Friendly Systems for Bioactive Compounds’ Delivery: State-of-the Art and Challenges. Materials 2023;16. https://doi.org/10.3390/ma16247550.

[82] Nano-and Microencapsulation Techniques and Applications Edited by Nedal Abu-Thabit. n.d.

[83] Vermelho AB, Moreira JV, Junior AN, da Silva CR, Cardoso V da S, Akamine IT. Microbial Preservation and Contamination Control in the Baking Industry. Fermentation 2024;10. https://doi.org/10.3390/fermentation10050231.

[84] Martau GA, Mihai M, Vodnar DC. The use of chitosan, alginate, and pectin in the biomedical and food sector-biocompatibility, bioadhesiveness, and biodegradability. Polymers (Basel) 2019;11. https://doi.org/10.3390/polym11111837.

[85] Ramachandraiah K, Han SG, Chin KB. Nanotechnology in meat processing and packaging: Potential applications - A review. Asian-Australas J Anim Sci 2015;28:290–302. https://doi.org/10.5713/ajas.14.0607.

[86] Shafique B, Ranjha MMAN, Murtaza MA, Walayat N, Nawaz A, Khalid W, et al. Recent Trends and Applications of Nanoencapsulated Bacteriocins against Microbes in Food Quality and Safety. Microorganisms 2023;11. https://doi.org/10.3390/microorganisms11010085.

[87] Laux P, Tentschert J, Riebeling C, Braeuning A, Creutzenberg O, Epp A, et al. Nanomaterials: certain aspects of application, risk assessment and risk communication. Arch Toxicol 2018;92:121–41. https://doi.org/10.1007/s00204-017-2144-1.

[88] Chakraborty C, Sharma AR, Sharma G, Lee SS. Zebrafish: A complete animal model to enumerate the nanoparticle toxicity. J Nanobiotechnology 2016;14. https://doi.org/10.1186/s12951-016-0217-6.

[89] Klaine SJ, Koelmans AA, Horne N, Carley S, Handy RD, Kapustka L, et al. Paradigms to assess the environmental impact of manufactured nanomaterials. Environ Toxicol Chem 2012;31:3–14. https://doi.org/10.1002/etc.733.

[90] Falkner R, Jaspers N. Regulating nanotechnologies: Risk, uncertainty and the global governance gap. Glob Environ Polit 2012;12:30–55. https://doi.org/10.1162/GLEP_a_00096.

[91] Risk Assessment and Risk Management of Nanomaterials in the Workplace: Translating Research to Practice. Ann Occup Hyg 2012. https://doi.org/10.1093/annhyg/mes040.

[92] Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005;113:823–39. https://doi.org/10.1289/ehp.7339.

[93] Kardani SL, Seth AK. Nanocarrier-based formulations: Regulatory Challenges, Ethical and Safety Considerations in Pharmaceuticals. vol. 18. n.d.

[94] McDonald J. Domestic regulation, international standards, and technical barriers to trade. World Trade Review 2005;4:249–74. https://doi.org/10.1017/S1474745605002387.

[95] Marette S, Clemens R, Babcock BA. The Recent International and Regulatory Decisions about Geographical Indications. 2007.

[96] Depledge MH, Pleasants LJ, Lawton JH. Editorial: Nanomaterials and the environment: The views of the royal commission on environmental pollution (UK). Environ Toxicol Chem 2010;29:1–4. https://doi.org/10.1002/etc.35.

[97] Calderón-Jiménez B, Johnson ME, Montoro Bustos AR, Murphy KE, Winchester MR, Baudrit JRV. Silver nanoparticles: Technological advances, societal impacts, and metrological challenges. Front Chem 2017;5. https://doi.org/10.3389/fchem.2017.00006.

[98] Mela DJ, MWoolner E. Perspective: Total, added, or free? What kind of sugars should we be talking about? Advances in Nutrition 2018;9:63–9. https://doi.org/10.1093/advances/nmx020.

[99] Ngarize S, Makuch KE, Pereira R. The case for regulating nanotechnologies: International, european and national perspectives. Rev Eur Comp Int Environ Law 2013;22:131–45. https://doi.org/10.1111/reel.12029.

[100] Hooker NH, Caswell JA. A framework for evaluating non-tariff barriers to trade related to sanitary and phytosanitary regulation. J Agric Econ 1999;50:234–46. https://doi.org/10.1111/j.1477-9552.1999.tb00810.x.

[101] Zamathula Queen Sikhakhane Nwokediegwu, Onyeka Henry Daraojimba, Johnson Sunday Oliha, Alexander Obaigbena, Michael Ayorinde Dada, Michael Tega Majemite. Review of emerging contaminants in water: USA and African perspectives. International Journal of Science and Research Archive 2024;11:350–60. https://doi.org/10.30574/ijsra.2024.11.1.0073.

[102] Selck H, Handy RD, Fernandes TF, Klaine SJ, Petersen EJ. Nanomaterials in the aquatic environment: A European Union–United States perspective on the status of ecotoxicity testing, research priorities, and challenges ahead. Environ Toxicol Chem 2016;35:1055–67. https://doi.org/10.1002/etc.3385.

[103] Kumari R, Suman K, Karmakar S, Mishra V, Lakra SG, Saurav GK, et al. Regulation and safety measures for nanotechnology-based agri-products. Front Genome Ed 2023;5. https://doi.org/10.3389/fgeed.2023.1200987.

[104] Halamoda-Kenzaoui B, Holzwarth U, Roebben G, Bogni A, Bremer-Hoffmann S. Mapping of the available standards against the regulatory needs for nanomedicines. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2019;11. https://doi.org/10.1002/wnan.1531.